{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:35:30Z","timestamp":1792096530966,"version":"4.4.0"},"reference-count":79,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006501","name":"Cystic Fibrosis Foundation Therapeutics Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.eprac.2026.03.099","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T16:10:20Z","timestamp":1775059820000},"page":"1266-1273","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Obesity and Metabolic Complications in Cystic Fibrosis"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8631-4144","authenticated-orcid":false,"given":"Tasma","family":"Harindhanavudhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica E.","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nellie S.","family":"Hani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Moheet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.eprac.2026.03.099_bib1","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jpeds.2005.06.003","article-title":"Overweight and obesity in deltaF508 homozygous cystic fibrosis","volume":"147","author":"Kastner-Cole","year":"2005","journal-title":"J Pediatr"},{"issue":"4","key":"10.1016\/j.eprac.2026.03.099_bib2","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3945\/ajcn.112.051409","article-title":"Longitudinal trends in nutritional status and the relation between lung function and BMI in cystic fibrosis: a population-based cohort study","volume":"97","author":"Stephenson","year":"2013","journal-title":"Am J Clin Nutr"},{"issue":"5","key":"10.1016\/j.eprac.2026.03.099_bib3","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jcf.2022.03.010","article-title":"Obesity in Cystic fibrosis: prevalence, trends and associated factors data from the US cystic fibrosis foundation patient registry","volume":"21","author":"Szentpetery","year":"2022","journal-title":"J Cystic Fibrosis"},{"issue":"13","key":"10.1016\/j.eprac.2026.03.099_bib4","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.3390\/jcm13133652","article-title":"Nutritional trends in cystic fibrosis: insights from the Italian cystic fibrosis patient registry","volume":"13","author":"Salvatore","year":"2024","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.eprac.2026.03.099_bib5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jcf.2019.10.004","article-title":"Prevalence and factors associated with overweight and obesity in adults with cystic fibrosis: a single-center analysis","volume":"19","author":"Harindhanavudhi","year":"2020","journal-title":"J Cystic Fibrosis"},{"issue":"19","key":"10.1016\/j.eprac.2026.03.099_bib6","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.eprac.2026.03.099_bib7","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of Elexacaftor\/Tezacaftor\/Ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.eprac.2026.03.099_bib8","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","article-title":"Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis","volume":"21","author":"Petersen","year":"2022","journal-title":"J Cystic Fibrosis"},{"issue":"3","key":"10.1016\/j.eprac.2026.03.099_bib11","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.0740","article-title":"Association of body mass index with clinical outcomes in patients with cystic fibrosis: a systematic review and meta-analysis","volume":"5","author":"Nagy","year":"2022","journal-title":"JAMA Network Open"},{"issue":"8","key":"10.1016\/j.eprac.2026.03.099_bib12","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.jand.2020.03.015","article-title":"Academy of nutrition and dietetics: 2020 cystic fibrosis evidence analysis center evidence-based nutrition practice guideline","volume":"121","author":"McDonald","year":"2021","journal-title":"J Acad Nutr Diet"},{"issue":"6","key":"10.1016\/j.eprac.2026.03.099_bib13","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/0895-4356(88)90063-7","article-title":"A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto","volume":"41","author":"Corey","year":"1988","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"10.1016\/j.eprac.2026.03.099_bib14","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ncp.10251","article-title":"Association between fat-free mass and pulmonary function in patients with cystic fibrosis: a narrative review","volume":"34","author":"Gomes","year":"2019","journal-title":"Nutr Clin Pract"},{"key":"10.1016\/j.eprac.2026.03.099_bib15","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.rmed.2018.07.016","article-title":"Nutritional status and pulmonary outcome in children and young people with cystic fibrosis","volume":"142","author":"Papalexopoulou","year":"2018","journal-title":"Respir Med"},{"issue":"4","key":"10.1016\/j.eprac.2026.03.099_bib16","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.nut.2015.10.012","article-title":"Body composition and lung function in cystic fibrosis and their association with adiposity and normal-weight obesity","volume":"32","author":"Alvarez","year":"2016","journal-title":"Nutrition (Burbank, Los Angeles County, Calif)"},{"issue":"2","key":"10.1016\/j.eprac.2026.03.099_bib17","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3390\/nu14020310","article-title":"The relationship between body composition, dietary intake, physical activity, and pulmonary status in adolescents and adults with cystic fibrosis","volume":"14","author":"Scully","year":"2022","journal-title":"Nutrients"},{"issue":"6","key":"10.1016\/j.eprac.2026.03.099_bib18","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.pedneo.2023.11.006","article-title":"Pulmonary function and body composition parameters of children with cystic fibrosis from a hight complexity institution between 2015 and 2018","volume":"65","author":"Salazar-Solarte","year":"2024","journal-title":"Pediatr Neonatal"},{"issue":"4","key":"10.1016\/j.eprac.2026.03.099_bib19","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00174-2023","article-title":"Prevalence, risk factors and outcomes of cardiac disease in cystic fibrosis: a multinational retrospective cohort study","volume":"62","author":"Frost","year":"2023","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.eprac.2026.03.099_bib20","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1016\/j.jcf.2016.09.010","article-title":"Coronary artery disease in cystic fibrosis: an emerging concern?","volume":"15","author":"Skolnik","year":"2016","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.eprac.2026.03.099_bib21","article-title":"Coronary artery disease in patients with cystic fibrosis - a case series and review of the literature","volume":"30","author":"Sandouk","year":"2022","journal-title":"J Clin Transl Endocrinol"},{"issue":"6","key":"10.1016\/j.eprac.2026.03.099_bib22","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1183\/09031936.00044009","article-title":"Increased augmentation index in patients with cystic fibrosis","volume":"34","author":"Hull","year":"2009","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.eprac.2026.03.099_bib23","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jcf.2017.08.015","article-title":"Blood flow regulation and oxidative stress during submaximal cycling exercise in patients with cystic fibrosis","volume":"17","author":"Tucker","year":"2018","journal-title":"J Cystic Fibrosis"},{"issue":"9","key":"10.1016\/j.eprac.2026.03.099_bib24","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for cystic fibrosis Phe508del-Gating and -Residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.eprac.2026.03.099_bib25","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jcf.2024.11.009","article-title":"Cardiometabolic risk factors in adults with cystic fibrosis undergoing elexacaftor\/tezacaftor\/ivacaftor therapy","volume":"24","author":"Gramegna","year":"2025","journal-title":"J Cystic Fibrosis"},{"issue":"1","key":"10.1016\/j.eprac.2026.03.099_bib26","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jcf.2024.09.022","article-title":"Development of metabolic syndrome in people with cystic fibrosis one year after exposure to elexacaftor-tezacaftor-ivacaftor","volume":"24","author":"Ratti","year":"2025","journal-title":"J Cystic Fibrosis"},{"issue":"10","key":"10.1016\/j.eprac.2026.03.099_bib27","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfae256","article-title":"Kidney effects of triple CFTR modulator therapy in people with cystic fibrosis","volume":"17","author":"Gabai","year":"2024","journal-title":"Clin Kidney J"},{"issue":"3","key":"10.1016\/j.eprac.2026.03.099_bib28","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jcf.2020.11.014","article-title":"CFTR plays an important role in the regulation of vascular resistance and high-fructose\/salt-diet induced hypertension in mice","volume":"20","author":"Zhang","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.eprac.2026.03.099_bib29","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jcf.2019.04.001","article-title":"Cystic fibrosis dyslipidaemia: a cross-sectional study","volume":"18","author":"Nowak","year":"2019","journal-title":"J Cystic Fibrosis"},{"issue":"1","key":"10.1016\/j.eprac.2026.03.099_bib30","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jcf.2009.09.002","article-title":"Prevalence of dyslipidemia in adults with cystic fibrosis","volume":"9","author":"Rhodes","year":"2010","journal-title":"J Cystic Fibrosis"},{"issue":"3","key":"10.1016\/j.eprac.2026.03.099_bib31","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jcf.2012.08.012","article-title":"Hypertriglyceridemia is associated with insulin levels in adult cystic fibrosis patients","volume":"12","author":"Ishimo","year":"2013","journal-title":"J Cystic Fibrosis"},{"issue":"9","key":"10.1016\/j.eprac.2026.03.099_bib32","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1016\/j.clnu.2019.12.029","article-title":"Overweight, obesity and significant weight gain in adult patients with cystic fibrosis association with lung function and cardiometabolic risk factors","volume":"39","author":"Bonhoure","year":"2020","journal-title":"Clin Nutr (Edinburgh, Scotland)"},{"issue":"3","key":"10.1016\/j.eprac.2026.03.099_bib33","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/ppul.26823","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on lipid and fat-soluble vitamin levels and association with body mass index","volume":"59","author":"Patel","year":"2024","journal-title":"Pediatr Pulmonol"},{"issue":"6","key":"10.1016\/j.eprac.2026.03.099_bib34","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jcf.2023.10.002","article-title":"Alterations in lipids after initiation of highly effective modulators in people with cystic fibrosis","volume":"22","author":"Despotes","year":"2023","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.eprac.2026.03.099_bib35","article-title":"Cholesterol and triglyceride concentrations following 12-18 months of clinically prescribed elexacaftor-tezacaftor-ivacaftor-PROMISE sub-study","volume":"40","author":"Bass","year":"2025","journal-title":"J Clin Transl Endocrinol"},{"key":"10.1016\/j.eprac.2026.03.099_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/bcp.70460","article-title":"Long-term impact of Elexacaftor\/Tezacaftor\/ivacaftor on pulmonary, nutritional and metabolic outcomes in homozygous F508del cystic fibrosis patients: a real-world cohort study","author":"Perrotta","year":"2026","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.eprac.2026.03.099_bib37","doi-asserted-by":"crossref","first-page":"4744","DOI":"10.1111\/dom.15844","article-title":"Cystic fibrosis-related diabetes develops from a combination of insulin secretion defects and insulin resistance","volume":"26","author":"Bolduc","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.eprac.2026.03.099_bib38","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jcf.2019.01.009","article-title":"The main mechanism associated with progression of glucose intolerance in older patients with cystic fibrosis is insulin resistance and not reduced insulin secretion capacity","volume":"18","author":"Colomba","year":"2019","journal-title":"J Cystic Fibrosis"},{"issue":"5","key":"10.1016\/j.eprac.2026.03.099_bib39","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.2337\/diabetes.48.5.1082","article-title":"Hepatic insulin resistance and defects in substrate utilization in cystic fibrosis","volume":"48","author":"Hardin","year":"1999","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.eprac.2026.03.099_bib40","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1002\/ppul.26388","article-title":"The impact of Elexacaftor\/Tezacaftor\/Ivacaftor on body composition in a small cohort of youth with cystic fibrosis","volume":"58","author":"Granados","year":"2023","journal-title":"Pediatr Pulmonol"},{"issue":"Suppl 2","key":"10.1016\/j.eprac.2026.03.099_bib41","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S1569-1993(11)60006-4","article-title":"Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease","volume":"10","author":"Debray","year":"2011","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.eprac.2026.03.099_bib42","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jcf.2025.02.007","article-title":"Non-invasive evaluation of steatosis and fibrosis in the liver in adults patients living with cystic fibrosis","volume":"24","author":"Pi\u00f1ar-Guti\u00e9rrez","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"12","key":"10.1016\/j.eprac.2026.03.099_bib43","doi-asserted-by":"crossref","first-page":"761","DOI":"10.4254\/wjh.v11.i12.761","article-title":"Lumacaftor\/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients","volume":"11","author":"Kutney","year":"2019","journal-title":"World J Hepatol"},{"issue":"2","key":"10.1016\/j.eprac.2026.03.099_bib44","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jcf.2018.11.004","article-title":"Controlled attenuation parameter: a measure of hepatic steatosis in patients with cystic fibrosis","volume":"18","author":"Bader","year":"2019","journal-title":"J Cystic Fibrosis"},{"issue":"1","key":"10.1016\/j.eprac.2026.03.099_bib45","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4254\/wjh.v10.i1.34","article-title":"Risk factors for hepatic steatosis in adults with cystic fibrosis: similarities to non-alcoholic fatty liver disease","volume":"10","author":"Ayoub","year":"2018","journal-title":"World J Hepatol"},{"issue":"1","key":"10.1016\/j.eprac.2026.03.099_bib46","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jcf.2023.12.005","article-title":"Sleep breathing disorder frequency, risk factors, and treatment among adults with cystic fibrosis","volume":"23","author":"Maqsood","year":"2024","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.eprac.2026.03.099_bib47","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.sleep.2021.09.017","article-title":"Obstructive sleep apnea in children and adolescents with cystic fibrosis and preserved lung function or mild impairment: a systematic review and meta-analysis of prevalence","volume":"88","author":"de Sousa","year":"2021","journal-title":"Sleep Med"},{"issue":"4","key":"10.1016\/j.eprac.2026.03.099_bib48","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/ppul.25811","article-title":"Risk factors for obstructive sleep apnea in cystic fibrosis","volume":"57","author":"Shakkottai","year":"2022","journal-title":"Pediatr Pulmonology"},{"issue":"10","key":"10.1016\/j.eprac.2026.03.099_bib49","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1002\/ppul.27061","article-title":"Obstructive sleep apnea in children with cystic fibrosis on highly effective modulator therapy","volume":"59","author":"Shakkottai","year":"2024","journal-title":"Pediatr Pulmonol"},{"issue":"8","key":"10.1016\/j.eprac.2026.03.099_bib50","first-page":"766","article-title":"Effect of triple combination CFTR modulator therapy on sleep in adult patients with cystic fibrosis. Respiration","volume":"101","author":"Welsner","year":"2022","journal-title":"Int Rev Thorac Dis"},{"issue":"7","key":"10.1016\/j.eprac.2026.03.099_bib51","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.jand.2020.03.014","article-title":"Effect of CFTR modulators on anthropometric parameters in individuals with cystic fibrosis: an evidence analysis center systematic review","volume":"121","author":"Bailey","year":"2021","journal-title":"J Acad Nutr Diet"},{"issue":"1","key":"10.1016\/j.eprac.2026.03.099_bib52","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12931-023-02451-0","article-title":"Heterogeneity of weight gain after initiation of Elexacaftor\/Tezacaftor\/Ivacaftor in people with cystic fibrosis","volume":"24","author":"Gramegna","year":"2023","journal-title":"Respir Res"},{"issue":"19","key":"10.1016\/j.eprac.2026.03.099_bib53","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.3390\/nu16193293","article-title":"Impact of elexacaftor-tezacaftor-ivacaftor therapy on body composition, dietary intake, biomarkers, and quality of life in people with cystic fibrosis: a prospective observational study","volume":"16","author":"Hevilla","year":"2024","journal-title":"Nutrients"},{"issue":"12","key":"10.1016\/j.eprac.2026.03.099_bib54","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1002\/ppul.27272","article-title":"Effects on growth, weight and body composition after CFTR modulators in children with cystic fibrosis","volume":"59","author":"L\u00f3pez C\u00e1rdenes","year":"2024","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"10.1016\/j.eprac.2026.03.099_bib55","doi-asserted-by":"crossref","first-page":"9465","DOI":"10.1038\/s41598-024-59622-2","article-title":"Elexacaftor\/Tezacaftor\/Ivacaftor influences body composition in adults with cystic fibrosis: a fully automated CT-based analysis","volume":"14","author":"Westh\u00f6lter","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.eprac.2026.03.099_bib56","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.clnu.2025.09.008","article-title":"Body mass, linear growth, and body composition before and after the introduction of elexacaftor\/tezacaftor\/ivacaftor among children and adults with cystic fibrosis","volume":"54","author":"Bader-Larsen","year":"2025","journal-title":"Clin Nutr"},{"issue":"9","key":"10.1016\/j.eprac.2026.03.099_bib57","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.71280","article-title":"Elexacaftor\/Tezacaftor\/Ivacaftor effect on bone density and body composition: a retrospective analysis","volume":"60","author":"Trost","year":"2025","journal-title":"Pediatr Pulmonol"},{"issue":"8","key":"10.1016\/j.eprac.2026.03.099_bib58","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41430-025-01589-y","article-title":"A systematic review of the impact of Elexacaftor\/Tezacaftor\/Ivacaftor on body composition in people with cystic fibrosis","volume":"79","author":"Kinsey","year":"2025","journal-title":"Eur J Clin Nutr"},{"issue":"12","key":"10.1016\/j.eprac.2026.03.099_bib59","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1016\/j.clnu.2023.10.015","article-title":"A prospective study to assess the impact of a novel CFTR therapy combination on body composition in patients with cystic fibrosis with F508del mutation","volume":"42","author":"Knott-Torcal","year":"2023","journal-title":"Clin Nutr"},{"issue":"2","key":"10.1016\/j.eprac.2026.03.099_bib60","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/ppul.26243","article-title":"Effect of Trikafta on bone density, body composition and exercise capacity in CF: a pilot study","volume":"58","author":"Gur","year":"2023","journal-title":"Pediatr Pulmonol"},{"issue":"5","key":"10.1016\/j.eprac.2026.03.099_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2023.101466","article-title":"Effects of Elexacaftor\/Tezacaftor\/Ivacaftor triple combination therapy on glycaemic control and body composition in patients with cystic fibrosis-related diabetes","volume":"49","author":"Grancini","year":"2023","journal-title":"Diabetes Metab"},{"issue":"5","key":"10.1016\/j.eprac.2026.03.099_bib62","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jcf.2023.06.002","article-title":"Weight a minute: exploring the effect on weight and body composition after the initiation of elexacaftor\/tezacaftor\/ivacaftor in adults with CF","volume":"22","author":"Proud","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.eprac.2026.03.099_bib63","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jcf.2018.09.001","article-title":"IVACAFTOR restores FGF19 regulated bile acid homeostasis in cystic fibrosis patients with an S1251N or a G551D gating mutation","volume":"18","author":"van de Peppel","year":"2019","journal-title":"J Cystic Fibrosis"},{"issue":"4","key":"10.1016\/j.eprac.2026.03.099_bib64","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jcf.2024.05.005","article-title":"Impact of lumacaftor\/ivacaftor on nutrition and growth in modulator-na\u00efve children over 24 weeks","volume":"23","author":"Tindall","year":"2024","journal-title":"J Cystic Fibrosisc"},{"issue":"2","key":"10.1016\/j.eprac.2026.03.099_bib65","first-page":"252","article-title":"Nutritional status and circulating levels of fat-soluble vitamins in cystic fibrosis patients: a cohort study and evaluation of the effect of CFTR modulators","volume":"10","author":"Francalanci","year":"2023","journal-title":"Children (Basel, Switzerland)"},{"issue":"2","key":"10.1016\/j.eprac.2026.03.099_bib66","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/jpr3.70007","article-title":"Effect of cystic fibrosis modulator therapies on serum levels of fat-soluble vitamins","volume":"6","author":"Crehu\u00e1-Gaudiza","year":"2025","journal-title":"JPGN Reports"},{"key":"10.1016\/j.eprac.2026.03.099_bib67","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.clnu.2025.04.027","article-title":"Dietary intake remains unchanged while nutritional status improves in children and adults with cystic fibrosis on Elexacaftor\/Tezacaftor\/Ivacaftor","volume":"50","author":"Enaud","year":"2025","journal-title":"Clin Nutr (Edinburgh, Scotland)"},{"key":"10.1016\/j.eprac.2026.03.099_bib68","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jpeds.2018.05.018","article-title":"Energy balance and mechanisms of weight gain with ivacaftor treatment of cystic fibrosis gating mutations","volume":"201","author":"Stallings","year":"2018","journal-title":"J Pediatr"},{"issue":"6","key":"10.1016\/j.eprac.2026.03.099_bib69","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.jcf.2023.06.010","article-title":"Body mass index and nutritional intake following Elexacaftor\/Tezacaftor\/Ivacaftor modulator therapy in adults with cystic fibrosis","volume":"22","author":"Caley","year":"2023","journal-title":"J Cystic Fibrosis"},{"issue":"1","key":"10.1016\/j.eprac.2026.03.099_bib70","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s10620-015-3834-2","article-title":"Nutritional status improved in cystic fibrosis patients with the G551D mutation after treatment with Ivacaftor","volume":"61","author":"Borowitz","year":"2016","journal-title":"Dig Dis Sci"},{"issue":"5","key":"10.1016\/j.eprac.2026.03.099_bib71","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jada.2008.02.020","article-title":"Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review","volume":"108","author":"Stallings","year":"2008","journal-title":"J Am Diet Assoc"},{"issue":"1","key":"10.1016\/j.eprac.2026.03.099_bib72","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jcf.2019.05.007","article-title":"Highlights from the nutrition guidelines for cystic fibrosis in Australia and New Zealand","volume":"19","author":"van der Haak","year":"2020","journal-title":"J Cystic Fibrosis"},{"issue":"3","key":"10.1016\/j.eprac.2026.03.099_bib73","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.clnu.2016.03.004","article-title":"ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis","volume":"35","author":"Turck","year":"2016","journal-title":"Clin Nutr (Edinburgh, Scotland)"},{"issue":"2","key":"10.1016\/j.eprac.2026.03.099_bib74","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.clnu.2023.12.017","article-title":"ESPEN-ESPGHAN-ECFS guideline on nutrition care for cystic fibrosis","volume":"43","author":"Wilschanski","year":"2024","journal-title":"Clin Nutr (Edinburgh, Scotland)"},{"issue":"5","key":"10.1016\/j.eprac.2026.03.099_bib75","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jcf.2023.05.010","article-title":"Nutritional considerations for a new era: a CF foundation position paper","volume":"22","author":"Leonard","year":"2023","journal-title":"J Cystic Fibrosis"},{"issue":"11","key":"10.1016\/j.eprac.2026.03.099_bib76","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.eprac.2025.07.017","article-title":"American Association of Clinical Endocrinology Consensus statement: algorithm for the evaluation and treatment of adults with Obesity\/Adiposity-Based chronic disease - 2025 update","volume":"31","author":"Nadolsky","year":"2025","journal-title":"Endocr Pract"},{"key":"10.1016\/j.eprac.2026.03.099_bib77","series-title":"Clinical management of obesity","author":"Apovian","year":"2025"},{"issue":"Suppl 2","key":"10.1016\/j.eprac.2026.03.099_bib78","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.jcf.2019.08.015","article-title":"Energy balance and obesity in individuals with cystic fibrosis","volume":"18","author":"Litvin","year":"2019","journal-title":"J Cystic Fibrosis"},{"issue":"9","key":"10.1016\/j.eprac.2026.03.099_bib79","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1111\/dom.16516","article-title":"Glucagon-like peptide-1 receptor agonists in adults with cystic fibrosis-related diabetes: rationale and emerging evidence","volume":"27","author":"Assalia Naffa","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eprac.2026.03.099_bib80","article-title":"Glucagon-like peptide1 receptor agonist treatment of cystic fibrosis-related diabetes complicated by obesity: a cases series and literature review","volume":"38","author":"Ahmed","year":"2024","journal-title":"J Clin Transl Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2026.03.099_bib81","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jcf.2024.08.005","article-title":"Glucagon-like-peptide-1 agonist therapy in adults with cystic fibrosis","volume":"24","author":"Park","year":"2025","journal-title":"J Cystic Fibrosis"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26009249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26009249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T09:54:16Z","timestamp":1785837256000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X26009249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":79,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1530891X26009249"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2026.03.099","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Obesity and Metabolic Complications in Cystic Fibrosis","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2026.03.099","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}